181 related articles for article (PubMed ID: 31414662)
1. [Therapeutic approaches targeting HIV reservoirs].
Cheret A
Virologie (Montrouge); 2019 Aug; 23(4):250-259. PubMed ID: 31414662
[TBL] [Abstract][Full Text] [Related]
2. Clinical Interventions in HIV Cure Research.
Rasmussen TA; Søgaard OS
Adv Exp Med Biol; 2018; 1075():285-318. PubMed ID: 30030798
[TBL] [Abstract][Full Text] [Related]
3. Which therapeutic strategy will achieve a cure for HIV-1?
Cillo AR; Mellors JW
Curr Opin Virol; 2016 Jun; 18():14-9. PubMed ID: 26985878
[TBL] [Abstract][Full Text] [Related]
4. Chimeric Antigen Receptor T Cells Guided by the Single-Chain Fv of a Broadly Neutralizing Antibody Specifically and Effectively Eradicate Virus Reactivated from Latency in CD4+ T Lymphocytes Isolated from HIV-1-Infected Individuals Receiving Suppressive Combined Antiretroviral Therapy.
Liu B; Zou F; Lu L; Chen C; He D; Zhang X; Tang X; Liu C; Li L; Zhang H
J Virol; 2016 Nov; 90(21):9712-9724. PubMed ID: 27535056
[TBL] [Abstract][Full Text] [Related]
5. Stimulating the RIG-I pathway to kill cells in the latent HIV reservoir following viral reactivation.
Li P; Kaiser P; Lampiris HW; Kim P; Yukl SA; Havlir DV; Greene WC; Wong JK
Nat Med; 2016 Jul; 22(7):807-11. PubMed ID: 27294875
[TBL] [Abstract][Full Text] [Related]
6. Between a shock and a hard place: challenges and developments in HIV latency reversal.
Zerbato JM; Purves HV; Lewin SR; Rasmussen TA
Curr Opin Virol; 2019 Oct; 38():1-9. PubMed ID: 31048093
[TBL] [Abstract][Full Text] [Related]
7. Alternate NF-κB-Independent Signaling Reactivation of Latent HIV-1 Provirus.
Acchioni C; Remoli AL; Marsili G; Acchioni M; Nardolillo I; Orsatti R; Farcomeni S; Palermo E; Perrotti E; Barreca ML; Sabatini S; Sandini S; Parolin C; Lin R; Borsetti A; Hiscott J; Sgarbanti M
J Virol; 2019 Sep; 93(18):. PubMed ID: 31243131
[TBL] [Abstract][Full Text] [Related]
8. Shocking HIV out of hiding: where are we with clinical trials of latency reversing agents?
Rasmussen TA; Lewin SR
Curr Opin HIV AIDS; 2016 Jul; 11(4):394-401. PubMed ID: 26974532
[TBL] [Abstract][Full Text] [Related]
9. Getting the "Kill" into "Shock and Kill": Strategies to Eliminate Latent HIV.
Kim Y; Anderson JL; Lewin SR
Cell Host Microbe; 2018 Jan; 23(1):14-26. PubMed ID: 29324227
[TBL] [Abstract][Full Text] [Related]
10. A New Quinoline BRD4 Inhibitor Targets a Distinct Latent HIV-1 Reservoir for Reactivation from Other "Shock" Drugs.
Abner E; Stoszko M; Zeng L; Chen HC; Izquierdo-Bouldstridge A; Konuma T; Zorita E; Fanunza E; Zhang Q; Mahmoudi T; Zhou MM; Filion GJ; Jordan A
J Virol; 2018 May; 92(10):. PubMed ID: 29343578
[TBL] [Abstract][Full Text] [Related]
11. Targeting Cellular and Tissue HIV Reservoirs With Toll-Like Receptor Agonists.
Macedo AB; Novis CL; Bosque A
Front Immunol; 2019; 10():2450. PubMed ID: 31681325
[TBL] [Abstract][Full Text] [Related]
12. Exploring the potential of monoclonal antibody therapeutics for HIV-1 eradication.
Euler Z; Alter G
AIDS Res Hum Retroviruses; 2015 Jan; 31(1):13-24. PubMed ID: 25385703
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic Targeting of HIV Reservoirs: How to Give T Cells a New Direction.
Yang H; Wallace Z; Dorrell L
Front Immunol; 2018; 9():2861. PubMed ID: 30564246
[TBL] [Abstract][Full Text] [Related]
14. Relationship between Measures of HIV Reactivation and Decline of the Latent Reservoir under Latency-Reversing Agents.
Petravic J; Rasmussen TA; Lewin SR; Kent SJ; Davenport MP
J Virol; 2017 May; 91(9):. PubMed ID: 28202759
[TBL] [Abstract][Full Text] [Related]
15. Class 1-Selective Histone Deacetylase (HDAC) Inhibitors Enhance HIV Latency Reversal while Preserving the Activity of HDAC Isoforms Necessary for Maximal HIV Gene Expression.
Zaikos TD; Painter MM; Sebastian Kettinger NT; Terry VH; Collins KL
J Virol; 2018 Mar; 92(6):. PubMed ID: 29298886
[TBL] [Abstract][Full Text] [Related]
16. Cat and Mouse: HIV Transcription in Latency, Immune Evasion and Cure/Remission Strategies.
Delannoy A; Poirier M; Bell B
Viruses; 2019 Mar; 11(3):. PubMed ID: 30889861
[TBL] [Abstract][Full Text] [Related]
17. Therapeutics for HIV-1 reactivation from latency.
Sgarbanti M; Battistini A
Curr Opin Virol; 2013 Aug; 3(4):394-401. PubMed ID: 23810462
[TBL] [Abstract][Full Text] [Related]
18. Maraviroc Is Associated with Latent HIV-1 Reactivation through NF-κB Activation in Resting CD4
Madrid-Elena N; García-Bermejo ML; Serrano-Villar S; Díaz-de Santiago A; Sastre B; Gutiérrez C; Dronda F; Coronel Díaz M; Domínguez E; López-Huertas MR; Hernández-Novoa B; Moreno S
J Virol; 2018 May; 92(9):. PubMed ID: 29444937
[TBL] [Abstract][Full Text] [Related]
19. Ingenol derivates promising for HIV eradication.
Poveda E
AIDS Rev; 2014; 16(4):246. PubMed ID: 25373349
[TBL] [Abstract][Full Text] [Related]
20. What Will It Take to Cure HIV?
Ananworanich J
Top Antivir Med; 2015; 23(2):80-4. PubMed ID: 26200707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
